ANDRAS FENYVES: Open Payments
NPI 1952467318 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$454 in 20 payments from 10 companies in 2025. Trend: 2023 $255 · 2024 $589 · 2025 $454
Food & beverage: $454
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 3 | $80 |
| ABBVIE INC. | 4 | $76 |
| Biogen, Inc. | 4 | $67 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Amgen Inc. | 2 | $37 |
| Novo Nordisk Inc | 1 | $34 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $34 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $23 |
Products named: MAVYRET, SKYCLARYS, MOUNJARO, REXULTI, OTEZLA, Ozempic, Kerendia, ZEPBOUND.
Industry payments across NY — which companies pay providers there.
